Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
Inja Waldhauer, Valeria Gonzalez‐Nicolini, Anne Freimoser–Grundschober, Tapan K. Nayak, Linda Fahrni, Ralf J. Hosse, Danny Gerrits, E.J. Geven, Johannes Sam, Sabine M. Lang, Esther Bommer, Virginie Steinhart, Elisabeth Husar, Sara Colombetti, Erwin van Puijenbroek, Markus Neubauer, J. Mark Cline, Pradeep Garg, Gregory O. Dugan, Federica Cavallo, Gonzalo Acuña, Jehad Charo, Volker Teichgräber, Stefan Evers, Otto C. Boerman, Marina Bacac, Ekkehard Moessner, Pablo Umaña, Christian Klein
Abstract
activity of therapeutic antibodies that mediate antibody-dependent or T cell-dependent cellular cytotoxicity (TDCC) and of programmed death-ligand 1 (PD-L1) checkpoint inhibition. The triple combination of FAP-IL2v with an anti-PD-L1 antibody and an agonistic CD40 antibody was most efficacious. These data indicate that FAP-IL2v is a potent immunocytokine that potentiates the efficacy of different T- and NK-cell-based cancer immunotherapies.